The anti-atherogenic effects of berberine on foam cell formation are mediated through the upregulation of sirtuin 1

International Journal of Molecular Medicine

Volumn 34, Issue 4, 2014, Pages 1087-1093

  Chi, Liyi ^a   Peng, Lijing ^a   Pan, Na ^a   Hu, Xiaojing ^b   Zhang, Yanhai ^a  

^a Interventional Therapeutic Center   (China)

^b The Ninth Hospital of Xi'an City   (China)

Author keywords

Atherosclerosis; Berberine; Foam cell formation; Inflammation; Lipid metabolism; Sirtuin 1; THP 1 cells

Indexed keywords

ADENYLATE KINASE; ATORVASTATIN; BERBERINE; CHOLESTEROL; LIPOPOLYSACCHARIDE; MESSENGER RNA; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTECTIVE AGENT; SIRTUIN 1; SMALL INTERFERING RNA; HEPTANOIC ACID DERIVATIVE; LOW DENSITY LIPOPROTEIN; PYRROLE DERIVATIVE;

ANTIATHEROGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FOAM CELL; GENE TARGETING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIPID STORAGE; MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ATHEROSCLEROSIS; DRUG EFFECTS; METABOLISM; PATHOLOGY;

ADENYLATE KINASE; ATHEROSCLEROSIS; BERBERINE; CHOLESTEROL; FOAM CELLS; HEPTANOIC ACIDS; HUMANS; LIPOPROTEINS, LDL; MACROPHAGES; PPAR GAMMA; PYRROLES; SIRTUIN 1; UP-REGULATION;

EID: 84907470716     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.1868     Document Type: Article

References (37)

1. Zhao JF, Jim Leu SJ, Shyue SK, Su KH, Wei J and Lee TS: Novel effect of paeonol on the formation of foam cells: promotion of LXRα-ABCA1-dependent cholesterol efflux in macrophages. Am J Chin Med 41: 1079-1096, 2013.
2. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685-1695, 2005.
3. Weber C, Zernecke A and Libby P: The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 8: 802-815, 2008.
4. Boring L, Gosling J, Cleary M and Charo IF: Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394: 894-897, 1998.
5. Edfeldt K, Swedenborg J, Hansson GK and Yan ZQ: Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 105: 1158-1161, 2002. (Pubitemid 34225814)
6. Li AC and Glass CK: The macrophage foam cell as a target for therapeutic intervention. Nat Med 8: 1235-1242, 2002. (Pubitemid 35373554)
7. Voloshyna I, Hai O, Littlefield MJ, Carsons S and Reiss AB: Resveratrol mediates anti-atherogenic effects on cholesterol flux in human macrophages and endothelium via PPARγ and adenosine. Eur J Pharmacol 698: 299-309, 2013.
8. Stein S, Lohmann C, Schafer N, et al: SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis. Eur Heart J 31: 2301-2309, 2010.
9. Picard F, Kurtev M, Chung N, et al: Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-γ. Nature 429: 771-776, 2004. (Pubitemid 38833129)
10. Vaziri H, Dessain SK, Ng Eaton E, et al: hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107: 149-159, 2001. (Pubitemid 33035942)
11. Zhang QJ, Wang Z, Chen HZ, et al: Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc Res 80: 191-199, 2008.
12. Huang Z, Dong F, Li S, et al: Berberine-induced inhibition of adipocyte enhancer-binding protein 1 attenuates oxidized low-density lipoprotein accumulation and foam cell formation in phorbol 12-myristate 13-acetate-induced macrophages. Eur J Pharmacol 690: 164-169, 2012.
13. Kong W, Wei J, Abidi P, et al: Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 10: 1344-1351, 2004. (Pubitemid 40022716)
14. Yin J, Xing H and Ye J: Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 57: 712-717, 2008. (Pubitemid 351608234)
15. Liu X, Li G, Zhu H, et al: Beneficial effect of berberine on hepatic insulin resistance in diabetic hamsters possibly involves in SREBPs, LXRα and PPARα transcriptional programs. Endocr J 57: 881-893, 2010.
16. Zhu X, Guo X, Mao G, et al: Hepatoprotection of berberine against hydrogen peroxide-induced apoptosis by upregulation of Sirtuin 1. Phytother Res 27: 417-421, 2013.
17. Guan S and Wang B: Effects of fosinopril and valsartan on expressions of ICAM-1 and NO in human umbilical vein endothelial cells. Chin Med J (Engl) 116: 923-927, 2003. (Pubitemid 36834059)
18. Winnik S, Stein S and Matter CM: SIRT1 - an anti-inflammatory pathway at the crossroads between metabolic disease and atherosclerosis. Curr Vasc Pharmacol 10: 693-696, 2012.
19. Vingtdeux V, Chandakkar P, Zhao H, Davies P and Marambaud P: Small-molecule activators of AMP-activated protein kinase (AMPK), RSVA314 and RSVA405, inhibit adipogenesis. Mol Med 17: 1022-1030, 2011.
20. Fullerton MD, Steinberg GR and Schertzer JD: Immunometabolism of AMPK in insulin resistance and atherosclerosis. Mol Cell Endocrinol 366: 224-234, 2013.
21. Canto C, Jiang LQ, Deshmukh AS, et al: Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab 11: 213-219, 2010.
22. Hardie DG: AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8: 774-785, 2007.
23. Charo IF and Taubman MB: Chemokines in the pathogenesis of vascular disease. Circ Res 95: 858-866, 2004. (Pubitemid 39435000)
24. McLaren JE, Michael DR, Ashlin TG and Ramji DP: Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog Lipid Res 50: 331-347, 2011.
25. Chen FL, Yang ZH, Liu Y, et al: Berberine inhibits the expression of TNFα, MCP-1, and IL-6 in AcLDL-stimulated macrophages through PPARγ pathway. Endocrine 33: 331-337, 2008.
26. Zhu GY, Zhu XL, Li RT, Liu TB, Shang DY and Zhang Y: Atorvastatin inhibits scavenger receptor A and monocyte chemoattractant protein-1 expressions in foam cell. Zhonghua Xin Xue Guan Bing Za Zhi 35: 666-669, 2007 (In Chinese).
27. Kawai H, Kurata T, Deguchi K, et al: Combination benefit of amlodipine plus atorvastatin treatment on carotid atherosclerosis in Zucker metabolic rats. Neurol Res 35: 181-186, 2013.
28. Guan S, Wang B, Li W, Guan J and Fang X: Effects of berberine on expression of LOX-1 and SR-BI in human macrophage-derived foam cells induced by ox-LDL. Am J Chin Med 38: 1161-1169, 2010.
29. Kunjathoor VV, Febbraio M, Podrez EA, et al: Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 277: 49982-49988, 2002. (Pubitemid 36014449)
30. Rader DJ and Pure E: Lipoproteins, macrophage function, and atherosclerosis: beyond the foam cell? Cell Metab 1: 223-230, 2005. (Pubitemid 43960611)
31. Abidi P, Zhou Y, Jiang JD and Liu J: Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. Arterioscler Thromb Vasc Biol 25: 2170-2176, 2005. (Pubitemid 41416317)
32. Brusq JM, Ancellin N, Grondin P, et al: Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 47: 1281-1288, 2006. (Pubitemid 43830720)
33. Li L, Sawamura T and Renier G: Glucose enhances human macrophage LOX-1 expression: role for LOX-1 in glucose-induced macrophage foam cell formation. Circ Res 94: 892-901, 2004. (Pubitemid 38490066)
34. Liang KW, Ting CT, Yin SC, et al: Berberine suppresses MEK/ERK-dependent Egr-1 signaling pathway and inhibits vascular smooth muscle cell regrowth after in vitro mechanical injury. Biochem Pharmacol 71: 806-817, 2006.
35. Yokozawa T, Ishida A, Kashiwada Y, Cho EJ, Kim HY and Ikeshiro Y: Coptidis Rhizoma: protective effects against peroxynitrite-induced oxidative damage and elucidation of its active components. J Pharm Pharmacol 56: 547-556, 2004. (Pubitemid 38455621)
36. Cho BJ, Im EK, Kwon JH, et al: Berberine inhibits the production of lysophosphatidylcholine-induced reactive oxygen species and the ERK1/2 pathway in vascular smooth muscle cells. Mol Cells 20: 429-434, 2005.
37. Wang ZH, Liu XL, Zhong M, et al: Pleiotropic effects of atorvastatin on monocytes in atherosclerotic patients. J Clin Pharmacol 50: 311-319, 2010.